4 hours ago
1
fatido
- Merck (NYSE:MRK) said on Monday that it will start late-stage clinical trials for its oral drug, MK-8527, aimed at preventing HIV.
- In partnership with the Gates Foundation, the MK-8527-010 trial will focus on evaluating MK-8527 is for women and adolescent girls
English (US) ·